TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7481533

Group type: EXPERIMENTAL
Intervention: Surveillance every 2 years (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveillance every 4 years (group B)
Number of subjects: 0
Study: 2105872

Group type: EXPERIMENTAL
Intervention: Triphasil (0.075 mg LNG, 0.040 mg EE2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trinordiol (0.075 mg LNG, 0.040 mg EE2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydroalcoholic solution (0.075 mg LNG, 0.040 mg EE2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All formulations (Triphasil, Trinordiol, Hydroalcoholic solution)
Number of subjects: 24
Study: 373956

Group type: EXPERIMENTAL
Intervention: Treatment center selection criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in eligibility criteria and procedural requirements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior experience of clinic staff in clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Population density and annual rate of cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rating given to a center at the time of selection
Number of subjects: 0
Study: 6833462

Group type: EXPERIMENTAL
Intervention: 2‐4 mg micronized estradiol given orally
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 4 mg estradiol orally
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3 mg estradiol applied cutaneously
Number of subjects: 38
Study: 31571571

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous, microfragmented adipose tissue
Number of subjects: 20
Study: 30538180

Group type: EXPERIMENTAL
Intervention: High saturated fat group (15% total energy)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Low saturated fat group (7% total energy)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Red meat protein source (12% energy)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: White meat protein source (12% energy)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nonmeat protein source (16% energy)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Higher alpha diversity
Number of subjects: 109
Study: 27748307

Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI)
Number of subjects: 100
Study: 25040840

Group type: COMPARATOR
Intervention: 0.2% plain ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: dexmedetomidine 0.5 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1.0 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1.5 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80
Study: 22246148

Group type: EXPERIMENTAL
Intervention: PIES intervention with tailoring
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PIES intervention without tailoring
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control condition (standard National Cancer Institute brochures)
Number of subjects: 72
Study: 20219398

Group type: EXPERIMENTAL
Intervention: Exposure in vivo treatment for back pain patients with low or moderate levels of catastrophizing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure in vivo treatment for back pain patients with high levels of catastrophizing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low change participants
Number of subjects: 0
Study: 17347859

Group type: EXPERIMENTAL
Intervention: Outox (250 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (250 ml)
Number of subjects: 30
Study: 16248468

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) training (90% of 1RM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Moderate Intensity (MI) training (70% of 1RM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low Intensity (LI) training (50% of 1RM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 64
Study: 11914748

Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) 200 mg orally for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10)
Number of subjects: 40
Study: 10414394

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg by Turbuhaler)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salbutamol (50 microg by Turbuhaler)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg by Diskhaler)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9422205

Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR expression measurement in patients after elective neurosurgery
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR expression measurement in dermatological patients receiving high dose systemic steroids
Number of subjects: 67
Study: 2137279

Group type: EXPERIMENTAL
Intervention: 40 mg nicorandil
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 60 mg nicorandil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7433476

Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.025%) ophthalmic solution, 2 drops 4 times daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31651367

Group type: EXPERIMENTAL
Intervention: Psychodynamic case formulations made by experienced clinicians using simple experience-near language
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inferred mechanisms component of the formulations
Number of subjects: 0
Study: 29698983

Group type: EXPERIMENTAL
Intervention: Resistance training (supervised thrice-weekly for 16 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 27504699

Group type: EXPERIMENTAL
Intervention: 16 week exercise-based fall prevention program including muscle strengthening and challenging balance training exercises, combined with a 12 week home-based exercise program
Number of subjects: 378

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 378
Study: 24505281

Group type: EXPERIMENTAL
Intervention: TSAT ≤20%
Number of subjects: 879

Group type: COMPARATOR
Intervention: TSAT 20-40%
Number of subjects: 879
Study: 22412976

Group type: EXPERIMENTAL
Intervention: Blue light-filtering IOLs
Number of subjects: 1690
Study: 20172547

Group type: EXPERIMENTAL
Intervention: Ketorolac and acetaminophen
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 55
Study: 17954515

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol plus promethazine
Number of subjects: 316

Group type: COMPARATOR
Intervention: Intramuscular haloperidol alone
Number of subjects: 316
Study: 16292955

Group type: EXPERIMENTAL
Intervention: Macro-optical digital bronchoscopes with image analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time airway color analysis imaging system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-D structure extraction from 2-D bronchoscope images using MDCT
Number of subjects: 0
Study: 12829647

Group type: EXPERIMENTAL
Intervention: NN2211 (7.5 micro g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9892294

Group type: EXPERIMENTAL
Intervention: Day treatment program (25 hours/week, 12 weeks duration)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Enhanced standard care (standard methadone maintenance plus weekly skills training group, 12 weeks duration)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Both interventions (day treatment and enhanced standard care)
Number of subjects: 291
Study: 7634948

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 103
Study: 2197314

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 72
Study: 7027923

Group type: EXPERIMENTAL
Intervention: Selective decontamination using nalidixic acid, co‐trimoxazole, or polymyxin for gram-negative rods; amphotericin B or nystatin for yeasts.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what treatment was used).
Number of subjects: 0
Study: 31468473

Group type: EXPERIMENTAL
Intervention: maraviroc-containing ART
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: tenofovir-containing ART
Number of subjects: 233
Study: 31290996

Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg orally twice daily) plus Bevacizumab (10 mg/kg intravenously on day 1 of each 14-day cycle)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab (10 mg/kg intravenously on day 1 of each 14-day cycle)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dasatinib plus Bevacizumab
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab
Number of subjects: 121
Study: 28650857

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) and Physical Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS and Physical Therapy
Number of subjects: 0
Study: 27737842

Group type: EXPERIMENTAL
Intervention: Azithromycin for prevention of COPD exacerbations
Number of subjects: 1107
Study: 25274861

Group type: EXPERIMENTAL
Intervention: Intracoronary uridine triphosphate (UTP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous adenosine (IV adenosine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intracoronary adenosine (IC adenosine)
Number of subjects: 25
Study: 22209181

Group type: EXPERIMENTAL
Intervention: 8mg dexamethasone intramuscular injection 1 hour preoperatively
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 20
Study: 19303940

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 17229423

Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 40 minutes
Number of subjects: 0
Study: 15179345

Group type: EXPERIMENTAL
Intervention: Conventional anesthesia plus isoflurane (ISO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional anesthesia after shifting to insulin (I‐CA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional anesthesia plus isoflurane after shifting to insulin (I‐ISO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anesthesia (CA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anesthesia (G‐CA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anesthesia plus isoflurane (G‐ISO)
Number of subjects: 60
Study: 12324494

Group type: EXPERIMENTAL
Intervention: Vitamin B(12) (0.4 mg), folic acid (0.8 mg), and vitamin B(6) (40 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vitamin B(12) and folic acid
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vitamin B(6)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 9637646

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (20 microg/h)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Epidural saline-intravenous fentanyl (20 microg/h)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Epidural saline-intravenous saline (control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (20 microg/h)
Number of subjects: 54
Study: 8059869

Group type: EXPERIMENTAL
Intervention: Sensory integration program (3 sessions of 45 minutes per week for 10 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 3189722

Group type: EXPERIMENTAL
Intervention: Topical beclomethasone dipropionate 100 micrograms in each nostril twice daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diprospan (betamethasone dipropionate 5 mg and betamethasone disodium phosphate 2 mg per ml) injection
Number of subjects: 30
Study: 31673708

Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic radiosurgery (NaSRS)
Number of subjects: 30
Study: 29703575

Group type: EXPERIMENTAL
Intervention: Encouragement during the 6-minute walk test
Number of subjects: 148

Group type: COMPARATOR
Intervention: No encouragement during the 6-minute walk test
Number of subjects: 148
Study: 27586678

Group type: EXPERIMENTAL
Intervention: Sirolimus- and probucol-eluting stent
Number of subjects: 870

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent
Number of subjects: 870
Study: 24815326

Group type: EXPERIMENTAL
Intervention: Aramchol 300 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aramchol 100 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22349644

Group type: EXPERIMENTAL
Intervention: Intervention group (behavior change around child television viewing)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (child safety)
Number of subjects: 67
Study: 20110638

Group type: EXPERIMENTAL
Intervention: Tumescent solution with a lidocaine concentration of 400 mg/l
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tumescent solution with a lidocaine concentration of 500 mg/l
Number of subjects: 200
Study: 18230379

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 40
Study: 16397311

Group type: EXPERIMENTAL
Intervention: Ethnic-specific diabetes education programme
Number of subjects: 104

Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 104
Study: 12894697

Group type: EXPERIMENTAL
Intervention: Mepilex Border
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tielle and Allevyn Adhesive
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Duoderm Extra Thin, Biatain, and Versiva
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tielle and Allevyn
Number of subjects: 24
Study: 10549449

Group type: EXPERIMENTAL
Intervention: Mefenamic acid, 500 mg twice a day for 5 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 67
Study: 8652318

Group type: EXPERIMENTAL
Intervention: Propofol sedation (initial i.v. boluses of 0.5 mg kg‐1 and fentanyl 1 microgram kg‐1, followed by an infusion of 50 micrograms kg‐1 min‐1)
Number of subjects: 36
Study: 8390014

Group type: COMPARATOR
Intervention: Sequential immunosuppression with ALG, azathioprine, and steroids for 14 days (group A)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Early start to cyclosporin A after 2 days (group B)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Group A (14 days treatment)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Group B (2 days treatment)
Number of subjects: 114
Study: 3323275

Group type: EXPERIMENTAL
Intervention: Diapers containing absorbent gelling material
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional cellulose core diapers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cloth diapers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolation of microorganisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus isolation
Number of subjects: 0
Study: 30286230

Group type: EXPERIMENTAL
Intervention: Escitalopram oxalate
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Baseline QIDS-SR score
Number of subjects: 125
Study: 28069072

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g × 4 and ibuprofen 400 mg × 4
Number of subjects: 556

Group type: COMPARATOR
Intervention: Paracetamol 1 g × 4 and placebo
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo and ibuprofen 400 mg × 4
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Paracetamol 0.5 g × 4 and ibuprofen 200 mg
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 556
Study: 26003070

Group type: EXPERIMENTAL
Intervention: PEP system
Number of subjects: 67

Group type: COMPARATOR
Intervention: No PEP
Number of subjects: 67
Study: 23572108

Group type: EXPERIMENTAL
Intervention: Soft-contact lenses (SCLs) with varying oxygen permeability
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High oxygen permeability lenses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Classical data-interpretation procedure
Number of subjects: 10
Study: 21654266

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Febuxostat 20 mg/d
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 19133287

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal night's sleep
Number of subjects: 14
Study: 16356696

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-80 mg)
Number of subjects: 144
Study: 15241721

Group type: EXPERIMENTAL
Intervention: Training Group 1 (TG1, n = 12): Plyometric training with rapid stretch contraction (0.4 m/s)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Training Group 2 (TG2, n = 12): Plyometric training with slow stretch contraction (0.2 m/s)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG, n = 6)
Number of subjects: 30
Study: 10932613

Group type: EXPERIMENTAL
Intervention: Cysplatin 60 mg/m2 and Etoposide 120 mg/m2 (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cysplatin 60 mg/m2 and Epirubicin 120 mg/m2 (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etoposide 120 mg/m2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2
Number of subjects: 50
Study: 8733686

Group type: EXPERIMENTAL
Intervention: 10 micrograms G‐CSF/kg BW per day (group A)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 24 micrograms G‐CSF/kg BW per day (group B)
Number of subjects: 67
Study: 1806953

Group type: EXPERIMENTAL
Intervention: Long-term cannabis users
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonuser controls
Number of subjects: 18
Study: 6304870

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (non-fasting)
Number of subjects: 12
Study: 31956722

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing embedded into usual physiotherapy care with a specifically designed app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 0
Study: 31126564

Group type: EXPERIMENTAL
Intervention: Olive oil massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo massage (liquid paraffin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 60
Study: 28969978

Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome (Exparel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride (Marcaine)
Number of subjects: 0
Study: 26095339

Group type: EXPERIMENTAL
Intervention: Dexamethasone 7.5 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Betamethasone 6.0 mg
Number of subjects: 56
Study: 23303417

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) and Lithium (Li)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) and Lithium (Li)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 21350201

Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm none/mild (0%-33% decrease in arterial diameter)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm moderate (34%-66% decrease in arterial diameter)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm severe (≥67% decrease in arterial diameter)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 381
Study: 19215547

Group type: EXPERIMENTAL
Intervention: Intramuscular carbetocin (100 microg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intramuscular syntometrine (0.5 mg ergometrine and 5IU oxytocin)
Number of subjects: 120
Study: 17410120

Group type: EXPERIMENTAL
Intervention: Thioridazine 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesoridazine 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15173145

Group type: EXPERIMENTAL
Intervention: Handwashing promotion and plain soap
Number of subjects: 3163

Group type: EXPERIMENTAL
Intervention: Antibacterial soap
Number of subjects: 3163

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3163
Study: 11692178

Group type: EXPERIMENTAL
Intervention: Sildenafil (25-100 mg)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 9137901

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 7982251

Group type: EXPERIMENTAL
Intervention: Felodipine-ER (5 mg once daily, increased to 10 mg if needed)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Nifedipine GITS (30 mg once daily, increased to 60 or 90 mg if needed)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Felodipine-ER
Number of subjects: 277

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 277
Study: 2972308

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (1 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (40 mg)
Number of subjects: 9
Study: 31065889

Group type: EXPERIMENTAL
Intervention: MoVo-LISA intervention (treatment as usual plus MoVo-LISA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 202
Study: 28483182

Group type: EXPERIMENTAL
Intervention: Acupressure (two sessions, each lasting 20 minutes, administered one hour and three hours after attending the women's division)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 120
Study: 25617026

Group type: EXPERIMENTAL
Intervention: Buccotherm®
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xeros®
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Marshmallow root
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 23264399

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21215550

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 2 g
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133